Plasma
Promoted content
Together toward a broader European plasma donation ecosystem
The unique aspects of human plasma need to be framed more precisely in the EU Blood Directive. The revision of the European Union Blood, Tissues and Cells Legislation brings an opportunity to strengthen this legal framework to encourage new approaches...Promoted content
Infographic: a health-economic assessment on immunoglobulin replacement therapy
This paper offers a health economic model to estimate the value of treatment with immunoglobulin replacement therapy (IgGRT) for CVID patients.Promoted content
Europe needs to collect more plasma
Plasma-derived medicinal products (PDMPs), derived from human plasma from healthy donors, are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin....Supporter
This stakeholder supports EURACTIV's coverage of Plasma. This support enables EURACTIV to devote additional editorial resources to cover the topic more widely and deeply. EURACTIV's editorial content is independent from the views of its supporters.
The Plasma Protein Therapeutics Association (PPTA) is the global industry trade association with a strong European presence representing the private sector manufacturers of plasma-derived medicinal products (PDMPs), and privately-owned plasma donation centres, which includes more than 150 centres in Europe. PPTA is steadfast in its mission to promote the availability of, and access to, safe and effective plasma protein therapies for patients around the world.
